Objective: To analyse whether hypertension during pregnancy is associated with early signs of impaired glucose metabolism in the offspring.

Design: Longitudinal study with a 5-year follow-up.

Setting: University Hospital, Göteborg, Sweden.

Main Outcome Measures: Fasting levels of glucose, insulin and C-peptide.

Subjects: Thirty-six children were born to mothers with hypertension in pregnancy. The children were divided into two groups according to their mothers' blood pressure at follow-up 7-12 years after pregnancy. Nineteen children had hypertensive mothers (HT), while 17 children had normotensive mothers at follow-up (NT). A control group (C) comprised 16 children, who were born after normotensive pregnancies to mothers who remained normotensive.

Results: Fasting plasma glucose was significantly higher in HT than in NT (5.2 vs. 4.9 mmol L-1; P < 0.05). In C fasting glucose was 5.1 mmol L-1. The same trend was seen for fasting insulin in HT. NT and C, respectively (6.7 vs. 4.7 vs. 5.3 microU mL-1). The C-peptide level was 1.61, 155 and 1.64 ng mL-1, respectively. Calculated insulin resistance was 1.5 in HT. 1.0 in NT and 1.2 in C.

Conclusions: It is suggested that hypertension during pregnancy may be associated with impaired glucose metabolism and elevated fasting glucose levels in the offspring during adolescence.

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1365-2796.1997.66890000.xDOI Listing

Publication Analysis

Top Keywords

hypertension pregnancy
16
glucose insulin
8
pregnancy associated
8
impaired glucose
8
glucose metabolism
8
children born
8
mmol l-1
8
fasting glucose
8
glucose
7
hypertension
5

Similar Publications

Purpose: To compare risks of neonatal anomalies and obstetric complications among frozen-thawed embryo transfer (FET), fresh embryo transfer (FreshET), and non-assisted reproductive technology (non-ART) treatments in infertile women.

Methods: This retrospective cohort study analyzed 7378 singleton births (2643 non-ART, 4219 FET, 516 FreshET) from 2013 to 2022. Outcomes were compared using inverse probability weighting regression adjustment, with adjustment for maternal factors.

View Article and Find Full Text PDF

KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary.

Kidney Int

February 2025

Institute of Physiology, University of Zurich, Zurich, Switzerland; Division of Nephrology, Cliniques universitaires Saint-Luc, UCLouvain Medical School, Brussels, Belgium. Electronic address:

The Kidney Disease: Improving Global Outcomes (KDIGO) 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) represents the first KDIGO guideline on this subject. Its scope includes nomenclature, diagnosis, prognosis, and prevalence; kidney manifestations; chronic kidney disease (CKD) management and progression, kidney failure, and kidney replacement therapy; therapies to delay progression of kidney disease; polycystic liver disease; intracranial aneurysms and other extrarenal manifestations; lifestyle and psychosocial aspects; pregnancy and reproductive issues; pediatric issues; and approaches to the management of people with ADPKD. The guideline has been developed with patient partners, clinicians, and researchers around the world, with the goal to generate a useful resource for healthcare providers and patients by providing actionable recommendations.

View Article and Find Full Text PDF

This study investigates the association between prenatal exposure to dioxin-like polychlorinated biphenyls (DL-PCBs) and glucocorticoid and androgenic hormone levels in cord blood. We analyzed cord blood samples from 500 mother-infant pairs from China (2022-2023), focusing on hormones including cortisol, cortisone, dehydroepiandrosterone (DHEA), and androstenedione. The main analysis revealed significant reductions in cortisol levels with increased exposure to PCB-77 (β = -3.

View Article and Find Full Text PDF

Preconception GLP-1 Receptor Agonist Use Associated with Decreased Risk for Adverse Obstetric Outcomes.

Am J Obstet Gynecol

January 2025

Department of Obstetrics and Gynecology, University Hospitals Cleveland Medical Center, Cleveland OH; Department of Reproductive Biology, Case Western Reserve University, Cleveland, OH. Electronic address:

Background: The use of glucagon-like-peptide-1 receptor agonists (GLP-1RAs) has greatly increased in patients of reproductive age within the past four years. However, there is minimal research into the long-term impact of these medications on future pregnancies.

Objectives: We aimed to evaluate the association between adverse obstetric outcomes and antecedent GLP-1RA use using a nationally representative database.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!